{
  "drug_name": "Azithromycin",
  "drug_class": "Unknown Class",
  "uses": "1 INDICATIONS AND USAGE Azithromycin is a macrolide antibacterial drug indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. Recommended dosages and durations of therapy in adult and pediatric patient populations vary in these indications. [see Dosage and Administration (2) ] Azithromycin is a macrolide antibacterial drug indicated for mild to moderate infections caused by designated, susceptible bacteria: \u2022 Acute bacterial exacerbations of chronic bronchitis in adults ( 1.1 ) \u2022 Acute bacterial sinusitis in adults ( 1.1 ) \u2022 Uncomplicated skin and skin structure infections in adults ( 1.1 ) \u2022 Urethritis and cervicitis in adults ( 1.1 ) \u2022 Genital ulcer disease in men ( 1.1 ) \u2022 Acute otitis media in pediatric patients (6 months of age and older) ( 1.2 ) \u2022 Community-acquired pneumonia in adults and pediatric patients (6...",
  "dosage_info": "2 DOSAGE AND ADMINISTRATION \u2022 Adult Patients ( 2.1 ) Infection Recommended Dose/Duration of Therapy Community-acquired pneumonia (mild severity) Pharyngitis/tonsillitis (second-line therapy) Skin/skin structure (uncomplicated) 500 mg as a single dose on Day 1, followed by 250 mg once daily on Days 2 through 5. Acute bacterial exacerbations of chronic bronchitis (mild to moderate) 500 mg as a single dose on Day 1, followed by 250 mg once daily on Days 2 through 5 or 500 mg once daily for 3 days. Acute bacterial sinusitis 500 mg once daily for 3 days. Genital ulcer disease (chancroid) Non-gonococcal urethritis and cervicitis One single 1 gram dose. Gonococcal urethritis and cervicitis One single 2 gram dose. \u2022 Pediatric Patients ( 2.2 ) Infection Recommended Dose/Duration of Therapy Acute otitis media (6 months of age and older) 30 mg/kg as a single dose or 10 mg/kg once daily for 3 days or 10...",
  "common_side_effects": "6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in labeling: \u2022 Hypersensitivity [see Warnings and Precautions (5.1) ] \u2022 Hepatotoxicity [see Warnings and Precautions (5.2) ] \u2022 Infantile Hypertrophic Pyloric Stenosis (IHPS) [see Warnings and Precautions (5.3) ] \u2022 QT Prolongation [see Warnings and Precautions (5.4) ] \u2022 Cardiovascular Death [see Warnings and Precautions (5.5) ] \u2022 Clostridioides difficile- Associated Diarrhea (CDAD) [see Warnings and Precautions (5.6) ] \u2022 Exacerbation of Myasthenia Gravis [see Warnings and Precautions (5.7) ] Most common adverse reactions are diarrhea (5 to 14%), nausea (3 to 18%), abdominal pain (3 to 7%), or vomiting (2 to 7%). ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Aurobindo Pharma USA, Inc. at 1-866-850-2876 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a...",
  "serious_side_effects": "5 WARNINGS AND PRECAUTIONS \u2022 Serious (including fatal) allergic and skin reactions: Discontinue azithromycin if reaction occurs. ( 5.1 ) \u2022 Hepatotoxicity: Severe, and sometimes fatal, hepatotoxicity has been reported. Discontinue azithromycin immediately if signs and symptoms of hepatitis occur. ( 5.2 ) \u2022 Infantile Hypertrophic Pyloric Stenosis (IHPS): Following the use of azithromycin in neonates (treatment up to 42 days of life), IHPS has been reported. Direct parents and caregivers to contact their physician if vomiting or irritability with feeding occurs. ( 5.3 ) \u2022 Prolongation of QT interval and cases of torsades de pointes have been reported. This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. ( 5.4 ) \u2022 Cardiovascular Death: Some observational studies have shown an approximately two-fold...",
  "contraindications": "4 CONTRAINDICATIONS \u2022 Patients with known hypersensitivity to azithromycin, erythromycin, any macrolide or ketolide drug. ( 4.1 ) \u2022 Patients with a history of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin. ( 4.2 ) 4.1 Hypersensitivity Azithromycin tablets are contraindicated in patients with known hypersensitivity to azithromycin, erythromycin, any macrolide or ketolide drug. 4.2 Hepatic Dysfunction Azithromycin tablets are contraindicated in patients with a history of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin.",
  "warnings": "",
  "source": "OpenFDA API"
}